Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 140 clinical trials
A Study of PF-06873600 in People With Cancer

able to participate in this study if they have the following types of cancer: Hormone Receptor positive (HR+) breast cancer; Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer that

  • 69 views
  • 03 Jul, 2022
  • 36 locations
A Study of SGN-STNV in Advanced Solid Tumors

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well …

adenocarcinoma
esophagus cancer
carcinoma
cancer of the ovary
esophageal cancer
  • 0 views
  • 05 Jul, 2022
  • 16 locations
Pre Operative Trastuzumab in Operable Breast Cancer

monoclonal antibody against the human epidermal growth factor receptor 2 (HER2/erbB-2),which has shown in both in vitro assays and in animals, to inhibit the proliferation of human tumour cells that

platelet count
endocrine therapy
gilbert's syndrome
epidermal growth factor
monoclonal antibodies
  • 71 views
  • 14 May, 2022
  • 1 location
Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer (CLOVER)

This is a prospective, multisite, randomized, open-label Phase III clinical trial (CLOVER study) comparing 4 cycles with 6 cycles of TC (docetaxel+cyclophosphamide) adjuvant chemotherapy for 1-3 positive lymph node, ER+/HER2- early breast cancer patients.

cyclophosphamide
carcinoma
invasive breast cancer
immunohistochemistry
immunostimulant
  • 6 views
  • 09 Apr, 2022
  • 14 locations
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans, and will be in two parts. The primary purpose of the parts are: Dose Escalation: To …

estrogen
endocrine therapy
solid tumour
epidermal growth factor
solid tumor
  • 280 views
  • 07 Jul, 2022
  • 14 locations
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.

proto-oncogene tyrosine-protein kinase ros
endocrine therapy
solid tumour
epidermal growth factor
pembrolizumab
  • 0 views
  • 16 Jun, 2022
  • 19 locations
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%. Therefore, the search for efficient and low toxicity alternatives has become a research hotspot. Our previous basic studies have shown that ER inhibitor fulvestrant and …

  • 0 views
  • 26 Jan, 2021
  • 1 location
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

  • 0 views
  • 09 Aug, 2022
  • 389 locations
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (TOUCH)

This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade, versus the treatment with paclitaxel in combination with HER2 blockade.

estrogen
primary tumor
endocrine therapy
her2/neu-positive breast cancer
metastasis
  • 17 views
  • 04 Feb, 2022
  • 47 locations
Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy (ATNEC)

The aim of this study is to assess whether, omitting further axillary treatment (ALND and ART) for patients with early stage breast cancer and axillary nodal metastases on needle biopsy, who after NACT have no residual cancer in the lymph nodes on sentinel node biopsy, is non-inferior to axillary treatment …

estrogen
sentinel node
progesterone receptor
progesterone
metastasis
  • 839 views
  • 14 Jun, 2022
  • 49 locations